At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 4 enrolled
Drug / intervention
nab-paclitaxeldrug
Likely dose
nab-paclitaxel 150 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma
Ohio State University Comprehensive Cancer Center·interventional·Posted Aug 20, 2008·Updated Feb 12, 2016
In Brief
A Phase 2 clinical trial evaluating nab-paclitaxel for Intraocular Melanoma. Completed, enrolled 4 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with metastatic melanoma of the eye that cannot be removed by surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntraocular Melanoma
CountriesUnited States
CollaboratorsNational Comprehensive Cancer Network, Celgene Corporation
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedAug 2008
Primary CompletionJul 2012
Study CompletionApr 2013
TodayJul 2026
First PostedAug 20, 2008
Enrollment StartAug 1, 2008
Primary CompletionJul 1, 2012
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 17.9 years ago
Interventions
nab-paclitaxeldrug
150 mg/m2 weekly for 3 of 4 weeks every 28 days.